Lilly says FDA approves expanded first-line CLL/SLL use for Jaypirca

• FDA cleared Lilly’s Jaypirca (pirtobrutinib) for first-line treatment of adults with CLL/SLL with no known 17p deletion.
• Decision expands Jaypirca beyond relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor.
• Approval relied on Phase 3 BRUIN CLL-313, where pirtobrutinib cut progression or death risk by 80% versus bendamustine-rituximab.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610021505PR_NEWS_USPR_____DE60021) on October 02, 2026, and is solely responsible for the information contained therein.